← Leaderboards
Anthony L Devico
University Of Md Biotechnology Institute
$11,565,862
Attributed
$12,894,217
Total exposure
12
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–23$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$12,894,217 · 12
By mechanism
R01$8,005,828 · 6
P01$3,687,851 · 3
R21$677,250 · 2
R61$523,288 · 1
Top collaborators
- Mohammad Mohseni Sajadi3 shared
- Krishanu Ray1 shared
Most similar at University Of Md Biotechnology Institute
Same institution · by research overlap
- James T. Stivers$16,239,758
- William Conrad Reid$1,544,214
- Kevin Donald Ridge$1,970,605
- John Moult$7,469,820
- Marvin S Reitz$1,929,003
Others in their field
Top investigators on “Hiv Infections”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,259,079
- Lawrence Corey · Fred Hutchinson Cancer Center$728,701,834
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$467,263,656
- Judith S. Currier · University Of California Los Angeles$466,447,923
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
Research focus
Hiv InfectionsHiv Envelope Protein Gp120ChemokineNeutralizing AntibodyCytokine ReceptorsHuman Immunodeficiency Virus 1Vaccine DevelopmentAntibodiesAnimalsLaboratory MouseResponseDoseHiv AntibodiesAntigensInfectionCd4 MoleculeBaseCellsVirusReceptor BindingClinical TrialsClinical ResearchSimian Human Immunodeficiency VirusVirus Infection Mechanism
Grant awards (34)
Novel bNAB-based treatment and prevention of HIV-1$766,942
R01 · FY2023 · AI
Detection Assays for Virion Susceptibility to HIV Broadly Neutralizing Antibodies in Plasma and Culture Fluids$523,288
R61 · FY2023 · AI
CCR5 determinants for the HIV transmitted founder phenotype$231,750
R21 · FY2023 · AI · contact PI
Novel bNAB-based treatment and prevention of HIV-1$629,056
R01 · FY2022 · AI
Novel bNAB-based treatment and prevention of HIV-1$737,425
R01 · FY2021 · AI
Project 1-Mechanism of Anti-Gp120 Antibody Persistence$481,790
P01 · FY2019 · AI · contact PI
Project 1-Mechanism of Anti-Gp120 Antibody Persistence$667,913
P01 · FY2018 · AI · contact PI
Project 1-Mechanism of Anti-Gp120 Antibody Persistence$546,198
P01 · FY2017 · AI · contact PI
Project 1-Mechanism of Anti-Gp120 Antibody Persistence$1,167,622
P01 · FY2016 · AI · contact PI
HIV Vaccines Based on GP120-CD4 Mimetic Complexes$345,323
R01 · FY2008 · AI · contact PI
HIV Vaccines Based on GP120-CD4 Mimetic Complexes$352,012
R01 · FY2007 · AI · contact PI
HIV Vaccines Based on GP120-CD4 Mimetic Complexes$480,034
R01 · FY2006 · AI · contact PI
Single Chain Complex Vaccines and Protective Immunity$439,302
R01 · FY2006 · AI · contact PI
Single Chain Complex Vaccines and Protective Immunity$818,899
R01 · FY2005 · AI
HIV Vaccines Based on GP120-CD4 Mimetic Complexes$315,563
R01 · FY2005 · AI
HIV Vaccines Based on GP120-CD4 Mimetic Complexes$64,324
R01 · FY2005 · AI
MACROPHAGE DERIVED CHEMOKINE AND HIV INFECTION$297,000
R01 · FY2003 · HL
CHEMOKINES: A MEASURE OF PEDIATRIC HIV DISEASE ACTIVITY$242,903
R01 · FY2003 · HD
CHEMOKINES: A MEASURE OF PEDIATRIC HIV DISEASE ACTIVITY$324,619
R01 · FY2002 · HD
MACROPHAGE DERIVED CHEMOKINE AND HIV INFECTION$297,000
R01 · FY2002 · HL
CD4-GP120 COMPLEX IMMUNOGENS$274,776
P01 · FY2002 · AI
CCR5 LIGANDS AS TOPICAL MICROBICIDES$0
P01 · FY2002 · AI
CHEMOKINES: A MEASURE OF PEDIATRIC HIV DISEASE ACTIVITY$318,206
R01 · FY2001 · HD
HIV-1 PASSIVE IMMUNITY AGAINST CORECEPTOR INTERACTIONS$311,378
R01 · FY2001 · HL
MACROPHAGE DERIVED CHEMOKINE AND HIV INFECTION$297,000
R01 · FY2001 · HL
CD4-GP120 COMPLEX IMMUNOGENS$274,776
P01 · FY2001 · AI
SINGLE CHAIN HIV GP120-CD4 COMPLEX$222,750
R21 · FY2001 · AI
CCR5 LIGANDS AS TOPICAL MICROBICIDES$0
P01 · FY2001 · AI
HIV-1 PASSIVE IMMUNITY AGAINST CORECEPTOR INTERACTIONS$342,056
R01 · FY2000 · HL
CHEMOKINES: A MEASURE OF PEDIATRIC HIV DISEASE ACTIVITY$309,748
R01 · FY2000 · HD
MACROPHAGE DERIVED CHEMOKINE AND HIV INFECTION$297,000
R01 · FY2000 · HL
CD4-GP120 COMPLEX IMMUNOGENS$274,776
P01 · FY2000 · AI
SINGLE CHAIN HIV GP120-CD4 COMPLEX$222,750
R21 · FY2000 · AI
HIV-1 PASSIVE IMMUNITY AGAINST CORECEPTOR INTERACTIONS$20,038
R01 · FY2000 · HL